DAVID POPLACK to Doxorubicin
This is a "connection" page, showing publications DAVID POPLACK has written about Doxorubicin.
Connection Strength
0.081
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
Score: 0.029
-
Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19; 86(2):143-5.
Score: 0.025
-
Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline. Isr J Med Sci. 1988 Sep-Oct; 24(9-10):477-82.
Score: 0.017
-
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):774-82.
Score: 0.007
-
Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. Cancer Treat Rep. 1978 Feb; 62(2):247-50.
Score: 0.002